Loading
Beamion LUNG-1 showed that zongertinib, a pill that blocks mutant HER2 while sparing EGFR, shrinks about seven in ten HER2-mutant lung cancers after chemotherapy, and it became the first oral HER2 drug approved for lung cancer.
Beamion LUNG-1 enrolled patients with advanced HER2-mutant non-small-cell lung cancer into a dose-finding phase and then expansion cohorts: previously treated patients naive to HER2-directed therapy, patients who had received a HER2 antibody-drug conjugate, and patients with non-tyrosine-kinase-domain mutations. Earlier HER2 inhibitors such as poziotinib and pyrotinib had produced modest responses with heavy EGFR-mediated diarrhoea and rash.
In the primary cohort of 75 previously treated patients the confirmed response rate was 71 percent, and 48 percent in 31 patients who had already received a HER2 antibody-drug conjugate. Diarrhoea and rash were mostly low grade and liver enzyme rises were the main reason for dose changes; interstitial lung disease was rare.
The FDA granted accelerated approval to zongertinib in August 2025 for previously treated HER2-mutant lung cancer. Beamion LUNG-2 is comparing it with standard first-line chemoimmunotherapy.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Confirmed objective response rateprimary | Zongertinib, previously treated, no prior HER2-directed therapy | 75 | 71% | - | - | link |
| Zongertinib after a HER2 antibody-drug conjugate | 31 | 48% |
Shares Zongertinib, Boehringer Ingelheim, HER2-mutant non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Zongertinib, HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, HER2.
Shares Zongertinib, Boehringer Ingelheim, HER2-mutant non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Zongertinib, Boehringer Ingelheim, Trastuzumab deruxtecan, Small-molecule kinase inhibitors.
Shares HER2 tyrosine kinase inhibitors, HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, HER2.
Shares HER2-mutant non-small-cell lung cancer, HER2, Small-molecule kinase inhibitors, Non-small-cell lung cancer.